DMRA Galecto, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.08
P/S
0.00
EV/EBITDA
2.06
DCF Value
$194.39
FCF Yield
-61.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-122.4%
ROA
-43.9%
ROIC
-46.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-27.8M | $— |
| Q4 null | $0.00 | $-200.7M | $— |
| FY null | $0.00 | $-209.8M | $— |
| Q3 null | $0.00 | $-3.1M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$40.00
Target (Median)
$40.00
Target Range
$40.00 - $40.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.51
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.